Serial No.: 10/552,931 Case No.: T1629YP

Page

2

AMENDMENTS TO THE CLAIMS

Please cancel Claims 1-26 and insert therefore Claims 27-31 as follow.

Listing of Claims:

Claims 1-26 (canceled)

27. (New) A compound of the formula I:

wherein:

Ar is benzisothiazol-3-yl or benzthiophen-3-yl, each of which bears substituent groups R^1 , R^2 and R^3 ;

 R^1 is hydrogen, fluorine, chlorine, bromine, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{2-6} alkenyloxy, C_{2-6} alkynyloxy, or C_{1-6} alkyl substituted with 1-5 fluorine atoms:

 R^2 is hydrogen, fluorine, chlorine, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkyl substituted with 1-5 fluorine atoms or C_{1-4} alkoxy substituted with 1-5 fluorine atoms;

R³ is hydrogen, fluorine, chlorine, methyl, methoxy, trifluoromethyl, difluoromethyl, trifluoromethoxy or difluoromethoxy;

Q¹ is hydrogen; fluorine; chlorine; bromine; C₁₋₆ alkyl; C₃₋₆ cycloalkyl; C₂₋₆ alkenyl; C₂₋₆ alkynyl; C₁₋₆ alkoxy; C₂₋₆ alkenyloxy; C₂₋₆ alkynyloxy; C₁₋₆ alkyl substituted with 1-5 fluorine atoms; nitrile; COQ⁴ or CO₂Q⁴ where Q⁴ is hydrogen or C₁₋₆ alkyl; NQ⁵Q⁶, CONQ⁵Q⁶ or SO₂NQ⁵Q⁶ where Q⁵ is hydrogen or C₁₋₆ alkyl and Q⁶ is hydrogen or C₁₋₆ alkyl or Q⁵ and Q⁶ are joined to form either a 4-7 membered heterocyclic ring which may also contain one oxygen or one further nitrogen ring atom, which heterocyclic ring may optionally be substituted by up to 3 fluorine atoms or by CF₃, methyl, ethyl or hydroxyl; hydroxyl; nitro; SOQ⁷ or SO₂Q⁷ where Q⁷ is C₁₋₄ alkyl;

Serial No.: 10/552,931 Case No.: T1629YP

Page 3

 NQ^8COQ^9 , $NQ^8CO_2Q^9$ or $NQ^8SO_2Q^9$ where Q^8 is hydrogen or C_{1-4} alkyl and Q^9 is hydrogen or C_{1-4} alkyl or is joined to Q^8 to form a 5-7 membered ring; a heteroaromatic ring of 5 ring atoms 1, 2, 3 or 4 of which may be nitrogen atoms or 1 or 2 of which are nitrogen atoms and 1 of which is an oxygen or sulfur atom or 1 of which is an oxygen or sulfur atom, which heteroaromatic ring optionally being substituted by methyl, ethyl or hydroxyl; or a heteroaromatic ring of 6 ring atoms containing 1 or 2 nitrogen ring atoms or a phenyl group either of which is optionally substituted by 1 or 2 fluorine or chlorine atoms or C_{1-4} alkyl, C_{1-4} alkoxy or trifluoromethyl groups;

 Q^2 is hydrogen, fluorine, chlorine, nitrile, hydroxy, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkyl substituted with 1-5 fluorine atoms, or C_{1-4} alkoxy substituted with 1-5 fluorine atoms;

Q³ is hydrogen, fluorine, chlorine, methyl, methoxy, trifluoromethyl, difluoromethyl, trifluoromethoxy or difluoromethoxy;

or Q² and Q³ are joined to form the residue of a 5, 6 or 7 membered carbocyclic ring;

```
R<sup>4</sup> is H or C<sub>1-4</sub> alkyl,
m is 0 or 1;
n is 0, 1 or 2; and
W is -CH<sub>2</sub>-, -CHF-, -CH(OH)- or -CO-;
or a pharmaceutically acceptable salt thereof.
```

28. (New) The compound of Claim 27 wherein Ar is benzisothiazol-3-yl or benzthiophen-3-yl, each bearing substituent groups R¹, R² and R³, m is 0 and n is 0.

Serial No.: 10/552,931 Case No.: T1629YP

Page

29. (New) The compound of Claim 27 wherein Q^1 is selected from the group consisting of: H, F, Cl, Br, CN, carboxamide, 5-membered heteroaryl and NQ^5Q^6 , where Q^5 and Q^6 complete a heterocyclic ring;

 Q^2 is H, F or Cl; Q^3 is H or F; R^1 is H, F, methyl or CF₃; R^2 is H, F, methyl or CF₃; and R^3 is H.

30. (New) A compound which is selected from the group consisting of: 4-({4-Fluoro-1-[(6-fluoro-1,2-benzisothiazol-3-yl)methyl]piperidin-4-yl}sulfonyl)benzonitrile; 6-Fluoro-3-({4-fluoro-4-[(4-fluorophenyl)sulfonyl]piperidin-1-yl}methyl)-1,2-benzisothiazole; or a pharmaceutically acceptable salt thereof

31. (New) A pharmaceutical composition comprising the compound of Claim 27 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.